Hasan Can Gudek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hasan Can Gudek has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Serkan Demir
Neurology Department, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey
5 shared publications - Damla Çetinkaya Tezer
Department of Neurology, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
4 shared publications - Ozlem Totuk
Neurology Department, Neurologist, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
4 shared publications - Sevki Sahin
University of Health Sciences, Hamidiye Faculty of Medicine, Department of Neurology, Sancaktepe Sehit Prof. Dr. Ilhan Varank SUAM, Turkey (Türkiye)
4 shared publications - İpek Güngör Doğan
Neurology Department, University of Health Sciences, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey
4 shared publications - Guldeniz Cetin Erci
Department of Neurology, Faculty of Medicine, Kocaeli University, Kocaeli 4100, Turkey
3 shared publications
Latest Publications
- 30 December 2025
- Published by Oxford University Press (OUP) in Archives of Clinical Neuropsychology
- Vol. 41 (3)
Differential Metacognitive Profiles in Relapsing–Remitting and Progressive Multiple Sclerosis: Associations with Fatigue, Cognition, and Perceived Disability
Objective: This study examined metacognitive belief profiles in individuals with multiple sclerosis (MS) and their associations with cognitive, emotional, and functional outcomes. Specifically, we compared relapsing–remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) to determine whether distinct metacognitive patterns characterize different disease phenotypes. Method: A total of 504 participants (75.6% RRMS, 9.9% SPMS, 14.5% PPMS) were recruited from a neurology clinic. Participants completed the Metacognitions Questionnaire-30 (MCQ-30), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Modified Fatigue Impact Scale (MFIS), Expanded Disability Status Scale (EDSS), Short Form-12 (SF-12), and Occupational Self-Assessment (OSA). Group differences were examined using ANOVA, correlations via Pearson coefficients, and hierarchical and ordinal regression models. Results: Progressive phenotypes, particularly PPMS, showed significantly higher maladaptive metacognitive beliefs than RRMS. RRMS individuals exhibited greater cognitive self-consciousness and need for control, whereas PPMS was associated with lower cognitive confidence and stronger negative beliefs about uncontrollability. No subtype differences emerged in positive beliefs. Maladaptive metacognition correlated with lower cognitive performance, greater fatigue, depressive symptoms, reduced quality of life, and lower self-efficacy. In regression models, depression was the strongest negative predictor of self-efficacy, while cognitive self-consciousness was a positive predictor. Clinical and psychological variables together explained 60% of the variance in self-efficacy. Metacognitive beliefs and fatigue also predicted higher neurological disability (EDSS). Conclusions: Metacognitive belief patterns differ across MS phenotypes and significantly impact both functional and neurological outcomes. These findings support incorporating metacognitive assessment into routine MS care and underscore the need for tailored psychological interventions addressing cognitive-emotional regulation.
- 30 December 2025
- Published by Oxford University Press (OUP) in Archives of Clinical Neuropsychology
- Vol. 41 (3)
Differential Metacognitive Profiles in Relapsing–Remitting and Progressive Multiple Sclerosis: Associations with Fatigue, Cognition, and Perceived Disability
Objective: This study examined metacognitive belief profiles in individuals with multiple sclerosis (MS) and their associations with cognitive, emotional, and functional outcomes. Specifically, we compared relapsing–remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) to determine whether distinct metacognitive patterns characterize different disease phenotypes. Method: A total of 504 participants (75.6% RRMS, 9.9% SPMS, 14.5% PPMS) were recruited from a neurology clinic. Participants completed the Metacognitions Questionnaire-30 (MCQ-30), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Modified Fatigue Impact Scale (MFIS), Expanded Disability Status Scale (EDSS), Short Form-12 (SF-12), and Occupational Self-Assessment (OSA). Group differences were examined using ANOVA, correlations via Pearson coefficients, and hierarchical and ordinal regression models. Results: Progressive phenotypes, particularly PPMS, showed significantly higher maladaptive metacognitive beliefs than RRMS. RRMS individuals exhibited greater cognitive self-consciousness and need for control, whereas PPMS was associated with lower cognitive confidence and stronger negative beliefs about uncontrollability. No subtype differences emerged in positive beliefs. Maladaptive metacognition correlated with lower cognitive performance, greater fatigue, depressive symptoms, reduced quality of life, and lower self-efficacy. In regression models, depression was the strongest negative predictor of self-efficacy, while cognitive self-consciousness was a positive predictor. Clinical and psychological variables together explained 60% of the variance in self-efficacy. Metacognitive beliefs and fatigue also predicted higher neurological disability (EDSS). Conclusions: Metacognitive belief patterns differ across MS phenotypes and significantly impact both functional and neurological outcomes. These findings support incorporating metacognitive assessment into routine MS care and underscore the need for tailored psychological interventions addressing cognitive-emotional regulation.
- Open Access
- 14 November 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 468
Sexual dysfunction in multiple sclerosis: prevalence, risk factors, and impact on quality of life in a large cohort study
Sexual dysfunction (SD) is a prevalent but underreported symptom in people with multiple sclerosis (pwMS), significantly affecting quality of life (QoL). Despite its clinical relevance, SD is often overlooked during routine care. This study aimed to determine the prevalence of SD, identify associated risk factors, assess its impact on depression and QoL, and explore help-seeking behaviors among pwMS. A cross-sectional study was conducted with 504 pwMS followed at a tertiary MS clinic between November 2023 and May 2024. Data on demographics, disease characteristics, and medications were collected. The Arizona Sexual Experiences Scale (ASEX) was used to assess SD, the Beck Depression Inventory (BDI) for depression, and the Short Form-12 (SF-12) for QoL. EDSS scores were used to evaluate disability. Statistical analyses included t-tests, ANOVA, chi-square, correlation analyses, and univariate and multivariate logistic regression, with significance set at p < 0.05. SD was identified in 69.0% of patients (73.9% of women, 57.6% of men). SD was significantly associated with female gender (p = 0.001), older age (p = 0.006), higher EDSS scores (p = 0.046), and increased depression levels (r = 0.38). SF-12 scores were significantly lower among those with SD (p < 0.001). In multivariate analysis, female gender (aOR = 2.01, p = 0.002) and higher BDI scores (aOR = 1.09, p < 0.001) remained independently associated with SD, while age and EDSS did not. No significant associations were found between SD and MS type, disease duration, or type of disease-modifying therapy. Only 9.8% of patients with SD sought medical help, while 83.1% did not seek support. SD is highly prevalent among pwMS and is closely linked to age, disability, depression, and reduced QoL. Depression emerged as a strong independent predictor. Despite this burden, most patients do not seek help. Multidisciplinary approaches and routine screening are essential to address SD in clinical settings.
- 14 November 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 468
Open AccessSexual dysfunction in multiple sclerosis: prevalence, risk factors, and impact on quality of life in a large cohort study
Sexual dysfunction (SD) is a prevalent but underreported symptom in people with multiple sclerosis (pwMS), significantly affecting quality of life (QoL). Despite its clinical relevance, SD is often overlooked during routine care. This study aimed to determine the prevalence of SD, identify associated risk factors, assess its impact on depression and QoL, and explore help-seeking behaviors among pwMS. A cross-sectional study was conducted with 504 pwMS followed at a tertiary MS clinic between November 2023 and May 2024. Data on demographics, disease characteristics, and medications were collected. The Arizona Sexual Experiences Scale (ASEX) was used to assess SD, the Beck Depression Inventory (BDI) for depression, and the Short Form-12 (SF-12) for QoL. EDSS scores were used to evaluate disability. Statistical analyses included t-tests, ANOVA, chi-square, correlation analyses, and univariate and multivariate logistic regression, with significance set at p < 0.05. SD was identified in 69.0% of patients (73.9% of women, 57.6% of men). SD was significantly associated with female gender (p = 0.001), older age (p = 0.006), higher EDSS scores (p = 0.046), and increased depression levels (r = 0.38). SF-12 scores were significantly lower among those with SD (p < 0.001). In multivariate analysis, female gender (aOR = 2.01, p = 0.002) and higher BDI scores (aOR = 1.09, p < 0.001) remained independently associated with SD, while age and EDSS did not. No significant associations were found between SD and MS type, disease duration, or type of disease-modifying therapy. Only 9.8% of patients with SD sought medical help, while 83.1% did not seek support. SD is highly prevalent among pwMS and is closely linked to age, disability, depression, and reduced QoL. Depression emerged as a strong independent predictor. Despite this burden, most patients do not seek help. Multidisciplinary approaches and routine screening are essential to address SD in clinical settings.
- Open Access
- 25 October 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (6) , 1023-1029
Impact of atrial fibrillation on cognitive decline and cortical atrophy in Alzheimer’s disease
Aims: This study aimed to evaluate the impact of atrial fibrillation (AF) on cognitive function and neuroradiological markers in patients with Alzheimer’s disease (AD). Methods: A total of 800 patients were screened at the Dementia Outpatient Clinic of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital. Thirty-three AD patients with confirmed AF were included, alongside 31 age-, sex, and education-matched AD patients without AF as controls. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), while mood symptoms were evaluated with the Geriatric Anxiety Scale and the Geriatric Depression Scale. Brain MRI scans were analyzed using Fazekas, Medial Temporal Atrophy (MTA), and Koedam scores. Due to the modest sample size, this study is best interpreted as exploratory in nature. Results: After six months, the AF-positive group exhibited a significant decline in MMSE scores, whereas the AF-negative group showed no significant change. Koedam scores were significantly higher in the AF-positive group, indicating more advanced cortical atrophy. Regression analysis revealed that AF had a borderline significant negative impact on cognitive performance after adjusting for baseline MMSE scores. Conclusion: AF may accelerate cognitive decline and is associated with greater cortical atrophy in patients with AD. These findings suggest that close cognitive monitoring and individualized care strategies may be beneficial in this population, though further research is needed to confirm this.
- 25 October 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (6) , 1023-1029
Open AccessImpact of atrial fibrillation on cognitive decline and cortical atrophy in Alzheimer’s disease
Aims: This study aimed to evaluate the impact of atrial fibrillation (AF) on cognitive function and neuroradiological markers in patients with Alzheimer’s disease (AD). Methods: A total of 800 patients were screened at the Dementia Outpatient Clinic of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital. Thirty-three AD patients with confirmed AF were included, alongside 31 age-, sex, and education-matched AD patients without AF as controls. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), while mood symptoms were evaluated with the Geriatric Anxiety Scale and the Geriatric Depression Scale. Brain MRI scans were analyzed using Fazekas, Medial Temporal Atrophy (MTA), and Koedam scores. Due to the modest sample size, this study is best interpreted as exploratory in nature. Results: After six months, the AF-positive group exhibited a significant decline in MMSE scores, whereas the AF-negative group showed no significant change. Koedam scores were significantly higher in the AF-positive group, indicating more advanced cortical atrophy. Regression analysis revealed that AF had a borderline significant negative impact on cognitive performance after adjusting for baseline MMSE scores. Conclusion: AF may accelerate cognitive decline and is associated with greater cortical atrophy in patients with AD. These findings suggest that close cognitive monitoring and individualized care strategies may be beneficial in this population, though further research is needed to confirm this.
- Open Access
- 21 July 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (7) , e70691
Exploring Social Cognition Sub‐Domains and Predictors in Multiple Sclerosis: A Cross‐Sectional Study
Background and purpose: Social cognition (SC) is increasingly recognized as a key cognitive domain affected in multiple sclerosis (MS), yet its sub‐domains and clinical correlates remain underexplored. This study aimed to assess different SC sub‐domains and identify their cognitive, emotional, and demographic predictors in people with MS (pwMS). Methods: This cross‐sectional study included 93 pwMS and 34 HCs. Assessments included the Reading the Mind in the Eyes Test (RMET) for emotion recognition, the Trail Making Test (TMT) for executive function, the Tromso Social Intelligence Scale (TSIS) for nonverbal understanding, the Implied Meaning Test (IMT) for implicit understanding, the Social‐Emotional Competence Scale for adaptability, the Barratt Impulsiveness Scale for impulsivity, the Stroop Test for inhibition, the Beck Depression Inventory (BDI) for depression, the Montreal Cognitive Assessment (MoCA) for cognition, and the Short Form‐12 (SF‐12) for quality of life (QoL). Multiple regression analyses were conducted to identify independent predictors of SC performance. Results: PwMS, particularly those with progressive MS, exhibited significantly lower SC performance across all sub‐domains compared to HCs. Regression analyses revealed that lower MoCA scores, higher BDI scores, and lower educational attainment were significant predictors of impaired SC, while disease duration and gender were not. Notably, SC deficits were also observed in cognitively preserved individuals, suggesting the relative independence of SC impairments. Conclusion: SC impairment is a distinct and clinically relevant feature of MS, associated with both cognitive and emotional factors. Routine SC screening may enhance patient care by informing personalized interventions. Future research should include larger cohorts, longitudinal designs, and practical SC assessment tools for clinical use.
- 21 July 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (7) , e70691
Open AccessExploring Social Cognition Sub‐Domains and Predictors in Multiple Sclerosis: A Cross‐Sectional Study
Background and purpose: Social cognition (SC) is increasingly recognized as a key cognitive domain affected in multiple sclerosis (MS), yet its sub‐domains and clinical correlates remain underexplored. This study aimed to assess different SC sub‐domains and identify their cognitive, emotional, and demographic predictors in people with MS (pwMS). Methods: This cross‐sectional study included 93 pwMS and 34 HCs. Assessments included the Reading the Mind in the Eyes Test (RMET) for emotion recognition, the Trail Making Test (TMT) for executive function, the Tromso Social Intelligence Scale (TSIS) for nonverbal understanding, the Implied Meaning Test (IMT) for implicit understanding, the Social‐Emotional Competence Scale for adaptability, the Barratt Impulsiveness Scale for impulsivity, the Stroop Test for inhibition, the Beck Depression Inventory (BDI) for depression, the Montreal Cognitive Assessment (MoCA) for cognition, and the Short Form‐12 (SF‐12) for quality of life (QoL). Multiple regression analyses were conducted to identify independent predictors of SC performance. Results: PwMS, particularly those with progressive MS, exhibited significantly lower SC performance across all sub‐domains compared to HCs. Regression analyses revealed that lower MoCA scores, higher BDI scores, and lower educational attainment were significant predictors of impaired SC, while disease duration and gender were not. Notably, SC deficits were also observed in cognitively preserved individuals, suggesting the relative independence of SC impairments. Conclusion: SC impairment is a distinct and clinically relevant feature of MS, associated with both cognitive and emotional factors. Routine SC screening may enhance patient care by informing personalized interventions. Future research should include larger cohorts, longitudinal designs, and practical SC assessment tools for clinical use.
- 27 December 2022
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 46 (2) , 82-84
Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin
Objective: Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe. However, if toxin enters the vascular space and gets through to peripheral cholinergic nerve terminals, it may lead to iatrogenic botulism. Method: We presented a patient who is diagnosed as iatrogenic botulism and treated with antitoxin at the 15th day of the exposure. Results: After the antitoxin administration, dramatical response to the treatment was observed. Conclusions: In this report, we want to evaluate a new case of iatrogenic botulism and emphasize the importance of antitoxin administration regardless the timing of the exposure for patients with progressing paralysis.
- 27 December 2022
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 46 (2) , 82-84
Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin
Objective: Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe. However, if toxin enters the vascular space and gets through to peripheral cholinergic nerve terminals, it may lead to iatrogenic botulism. Method: We presented a patient who is diagnosed as iatrogenic botulism and treated with antitoxin at the 15th day of the exposure. Results: After the antitoxin administration, dramatical response to the treatment was observed. Conclusions: In this report, we want to evaluate a new case of iatrogenic botulism and emphasize the importance of antitoxin administration regardless the timing of the exposure for patients with progressing paralysis.